The poly-(ADP-ribose)-polymerase (PARP) inhibitors olaparib and talazoparib are both useful treatment options for patients with advanced germline BRCA1/2-mutated triple-negative breast cancer (TNBC) or HER2-negative luminal-like breast cancer [43, 44]. Here, ERBB2 is linked to breast carcinoma.